文献速递心力衰竭与心肌病心律失常血脂与心血管预防

免疫检查点抑制剂相关心肌炎与心肌毒性

Immune Checkpoint Inhibitor Myocarditis and Myotoxicity.
PubMed 文献 · Circulation · 2026-08-31

免疫检查点抑制剂(ICI)相关心肌炎虽不常见,但可致命,现被视为ICI相关心肌毒性(ICI-M)这一系统性心肌肌肉综合征的一部分,可同时累及心肌、骨骼肌、传导系统等。肌钙蛋白升高不等于心肌炎,需结构化评估。ICI-M严重程度可分层,低危可密切监测,重症需住院监护、中断ICI及多学科免疫抑制治疗。

要点

  • ICI-M是累及心肌和骨骼肌的系统性综合征,涵盖心肌炎、肌炎、传导病、室性心律失常等。
  • 肌钙蛋白升高不等于心肌炎,需结合症状、心电图、肌酸激酶、影像及病理等结构化评估。
  • 重症ICI-M需监护住院、早期呼吸吞咽评估、中断ICI并快速多学科免疫抑制。

核心结论

  • ICI相关心肌炎应被视为ICI相关心肌毒性(ICI-M)这一系统性心肌肌肉综合征的一部分。
  • ICI-M严重程度可依据活动性胸腺瘤、心肌肌肉症状、低QRS电压、LVEF<50%及肌钙蛋白升高幅度进行分层。

研究设计与样本

  • 本文为综述,汇总多种数据来源的证据,重新定义ICI相关心肌炎为ICI-M。

主要发现

  • ICI-M可同时出现心肌炎、肌炎、传导疾病、室性心律失常、吞咽困难、假性肌无力眼球体征及呼吸肌衰竭。
  • ICI使用中肌钙蛋白升高不 synonymous 于心肌炎,应触发结构化评估。
  • 严重ICI-M需要监护住院、早期呼吸和吞咽评估、中断ICI及快速多学科免疫抑制。

关键数值与推荐

  • 严重程度分层依据:活动性胸腺瘤、心肌肌肉症状、低QRS电压、LVEF<50%、肌钙蛋白升高幅度。
  • 低风险病例(如仅有心脏生物标志物异常)可密切监测。
  • 皮质类固醇一般推荐;严重、进展或难治性疾病可考虑阿巴西普和鲁索替尼。
  • 阿巴西普抑制CD80/CD86-CD28共刺激,可滴定至单核细胞CD86受体占有率。
  • 鲁索替尼抑制JAK/STAT细胞因子信号通路,可能补充阿巴西普生物活性。

临床怎么用

  • 对ICI使用者出现肌钙蛋白升高应进行结构化评估,包括症状、心电图、肌钙蛋白和肌酸激酶、结构和功能评估及排除其他原因。
  • 低风险病例可密切监测,重症需监护住院、早期呼吸吞咽评估、中断ICI并快速多学科免疫抑制。
  • 皮质类固醇一般推荐;严重、进展或难治性疾病可考虑阿巴西普和鲁索替尼。
  • 再挑战通常避免,但可在严格监测下对选定患者重新评估。

局限性

  • 阿巴西普和鲁索替尼的证据有前景但非确定性,尚待前瞻性试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune checkpoint inhibitor (ICI)-associated myocarditis is uncommon but has been described as an important and potentially fatal complication of cancer treatment. Increasing evidence from a variety of data sources have reframed this complication as part of ICI-associated myotoxicity (ICI-M), a systemic cardiomuscular syndrome in which myocarditis, myositis, conduction disease, ventricular arrhythmias, dysphagia, pseudo-myasthenic oculobulbar signs, and respiratory muscle failure may coexist. Elevated troponin with ICI use is not synonymous with myocarditis but instead should trigger a structured evaluation that considers symptoms, ECG findings, troponin and creatine kinase concentrations, structural and functional assessments including left ventricular function, pathology when feasible, and exclusion of alternative causes including other cardiotoxic therapies. The severity of ICI-M is heterogeneous and can now be stratified using the presence of active thymoma, cardiomuscular symptoms, low QRS-voltage, left ventricular ejection fraction <50%, and magnitude of troponin elevation. Low-risk cases such as patients with abnormal cardiac biomarkers only may be monitored closely, whereas severe ICI-M requires monitored admission, early respiratory and swallowing assessment, ICI interruption, and rapid multidisciplinary immunosuppression. Corticosteroids are generally recommended; however, severe, progressive, or refractory disease increasingly supports pathophysiology-directed-based therapies, including abatacept and ruxolitinib. Abatacept inhibits CD80/CD86-CD28 co-stimulation and can be titrated to CD86 receptor occupancy of the monocytes. Ruxolitinib inhibits Janus kinase/signal transducer and activator of transcription cytokine signaling pathway and may complement abatacept bioactivity. Evidence is promising for these therapies but not definitive, pending prospective trials. Rechallenge is often avoided but could be reassessed in selected patients under strict surveillance.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Salem JE. Immune Checkpoint Inhibitor Myocarditis and Myotoxicity. Circulation. 2026. PMID: 42709038. doi:10.1161/CIRCULATIONAHA.126.081201

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。